Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

NVS - Novartis AG ADR - Stock Price & Dividends

Exchange: USA Stocks • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: US66987V1098

Cardiovascular, Immunology, Neuroscience, Oncology, Ophthalmology, Hematology

Novartis AG is a multinational healthcare company that discovers, develops, manufactures, and markets a wide range of healthcare products globally. The company's primary focus is on creating innovative prescription medicines that cater to the needs of patients and physicians.

Novartis AG has a diversified portfolio of therapeutic areas, including cardiovascular, renal and metabolic, immunology, neuroscience, oncology, ophthalmology, and hematology. This broad range of therapeutic areas enables the company to address various complex diseases and conditions, improving the quality of life for millions of people worldwide.

The company has formed strategic partnerships to advance its research and development efforts. For instance, Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a novel therapy designed to reduce low-density lipoprotein (LDL) cholesterol. This partnership aims to provide a new treatment option for patients with high cholesterol, a major risk factor for cardiovascular disease.

In addition, Novartis AG has partnered with Dawn Health to develop and commercialize Ekiva, a digital solution designed to support people living with Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare and debilitating blood disorder. This collaboration highlights the company's commitment to leveraging digital technologies to improve patient outcomes and enhance the overall healthcare experience.

Founded in 1996, Novartis AG is headquartered in Basel, Switzerland, and has established itself as a leader in the global healthcare industry. With a strong presence in over 140 countries, the company continues to innovate and expand its portfolio of life-changing medicines and therapies.

Drawdown (Underwater) Chart

Overall Trend and Yearly Seasonality

NVS Stock Overview

Market Cap in USD	217,793m
Sector	Healthcare
Industry	Drug Manufacturers - General
GiC SubIndustry	Pharmaceuticals
TER	0.00%
IPO / Inception	1991-11-18

NVS Stock Ratings

Growth 5y	56.8
Fundamental	46.1
Dividend	64.7
Rel. Performance vs Sector	0.05
Analysts	3.77/5
Fair Price Momentum	110.66 USD
Fair Price DCF	152.54 USD

NVS Dividends

Dividend Yield 12m	3.42%
Yield on Cost 5y	5.32%
Dividends CAGR 5y	6.21%
Payout Consistency	96.2%

NVS Growth Ratios

Growth 12m	16.18%
Growth Correlation 12m	58%
Growth Correlation 3m	79%
CAGR 5y	9.19%
CAGR/Mean DD 5y	1.40
Sharpe Ratio 12m	0.65
Alpha vs SP500 12m	2.31
Beta vs SP500 5y weekly	0.55
ValueRay RSI	68.80
Volatility GJR Garch 1y	19.93%
Price / SMA 50	4.15%
Price / SMA 200	11.64%
Current Volume	858.8k
Average Volume 20d	1513.2k

External Links for NVS Stock

News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle

What is the price of NVS stocks?
As of July 27, 2024, the stock is trading at USD 110.32 with a total of 858,849 shares traded.
Over the past week, the price has changed by +3.95%, over one month by +3.04%, over three months by +13.22% and over the past year by +15.38%.

What are the forecast for NVS stock price target?
According to ValueRays Forecast Model, NVS Novartis AG ADR will be worth about 121.2 in July 2025. The stock is currently trading at 110.32. This means that the stock has a potential upside of +9.84%.

Issuer	Forecast	Upside
Wallstreet Target Price	113.5	2.85
Analysts Target Price	112.8	2.20
ValueRay Target Price	121.2	9.84

Understanding Novartis AG ADR (NVS): A Comprehensive Overview

History of Novartis AG ADR

Novartis AG, a global healthcare company based in Switzerland, has a rich history that stretches back more than 250 years. It was formed in 1996 through the merger of two Swiss companies, Ciba-Geigy and Sandoz. These companies were themselves the result of several mergers and acquisitions over the years, making Novartis one of the oldest and most diversified healthcare companies in the world.

Core Business

Novartis focuses on three main sectors within the healthcare industry: pharmaceuticals, eye care, and generics through its Sandoz division. In the pharmaceuticals sector, Novartis is known for producing a wide range of medicines for various diseases, including cancer, heart disease, and more. Its eye care business, primarily under the Alcon brand until it was spun off in 2019, delivered innovative products to improve people’s sight. Sandoz, the generics and biosimilars division, aims to make high-quality medicines more accessible and affordable.

Side Businesses and Innovations

Beyond its core operations, Novartis has continually ventured into new business areas and innovations. Digital health initiatives, personalized medicine, and gene therapy are just a few fields where Novartis has made significant investments. The company is also known for its strong commitment to research and development (R&D), investing billions annually to discover new treatments and medical solutions.

Current Market Status

As of the latest financial results, Novartis AG ADR (NYSE:NVS) remains a giant in the healthcare sector, with a strong presence in over 100 countries. Despite facing challenges such as patent expirations and regulatory pressures, the company has sustained its growth through strategic acquisitions, divestitures, and a focus on high-growth areas in healthcare. The performance of Novartis in the stock market reflects its resilience and adaptability, making it a noteworthy entity in the global pharmaceutical and healthcare industry.